Pulmonary Cell News Volume 5.17 | May 5 2016

Expression of Histone Deacetylase 3 Instructs Alveolar Type I Cell Differentiation by Regulating a Wnt Signaling Niche in the Lung
Researchers demonstrated that inhibition of Wnt signaling causes defective alveolar type I (AT1) cell lineage differentiation ex vivo. Importantly, systemic activation of Wnt signaling at specific stages of lung development can partially rescue the AT1 cell differentiation defect in vivo. [Dev Biol] Abstract

MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis
The authors investigated the role of a novel kinase, MAP3K19, upregulated in idiopathic pulmonary fibrosis tissue, in TGF-β-induced signal transduction and in bleomycin-induced pulmonary fibrosis. MAP3K19 has a very limited tissue expression, restricted primarily to the lungs and trachea. [PLoS One] Full Article

Paeoniflorin Suppresses TGF-β Mediated Epithelial-Mesenchymal Transition in Pulmonary Fibrosis through a Smad-Dependent Pathway
In A549 cells, TGF-β1 stimulation induced epithelial-mesenchymal transition, as shown by the changes in cell morphology, the increased cell migration, and the increased vimentin and α-SMA expression as well as type I and type III collagen levels, and by the decreased E-cadherin expression. [Acta Pharmacol Sin] Abstract

Moracin M Inhibits Airway Inflammation by Interrupting the JNK/c-Jun and NF-κB Pathways In Vitro and In Vivo
Moracin M, O, and R were isolated from the root barks of Morus alba, and they inhibited interleukin (IL)−6 production from IL-1β-treated lung epithelial cells at 10 − 100 μM. [Eur J Pharmacol] Abstract

LUNG CANCER

Metformin Restores Crizotinib Sensitivity in Crizotinib-Resistant Human Lung Cancer Cells through Inhibition of IGF1-R Signaling Pathway
Researchers revealed that metformin effectively increased the sensitivity of both crizotinib-sensitive and -resistant non-small cell lung cancer cells to crizotinib, as evidenced by decreased proliferation and invasion and enhanced apoptosis. [Oncotarget] Full Article

Dexamethasone Suppresses the Growth of Human Non-Small Cell Lung Cancer via Inducing Estrogen Sulfotransferase and Inactivating Estrogen
Scientists explored the possibility that dexamethasone might be used as an endocrine therapeutic agent to treat human non-small cell lung cancer (NSCLC). The viability and proliferation of human NSCLC cell lines A549 and H1299 were assessed in vitro. [Acta Pharmacol Sin] Abstract

The Effects of Cordycepin on the Cell Proliferation, Migration and Apoptosis in Human Lung Cancer Cell Lines A549 and NCI-H460
The survival rate of A549 cells and NCI-H460 cells treated with cordycepin significantly decreased compared with untreated cells in a concentration-dependent manner, while the apoptosis rate increased. The migration number of cells treated with cordycepin significantly decreased as the increase in concentration. [J Pharm Pharmacol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Concert Pharmaceuticals Announces Positive Data from Multiple Dose Phase I Clinical Trial of CTP-656, Lead Candidate for the Treatment of Cystic Fibrosis
Concert Pharmaceuticals, Inc. announced positive topline data from a Phase I multiple ascending dose clinical trial of CTP-656. [Press release from Concert Pharmaceuticals, Inc. discussing research to be presented at the 39^th European Cystic Fibrosis Conference, Basel] Press Release

Sunovion Presents New Health Outcomes Data Supporting Brovana^® (Arformoterol Tartrate) Inhalation Solution in People with Moderate-to-Severe COPD
Sunovion Pharmaceuticals Inc. announced that new analyses of clinical and health outcomes data for Brovana^® Inhalation Solution will be presented. [Press release from Sunovion Pharmaceuticals Inc. discussing research to be presented at the 2016 American Thoracic Society International Conference (ATS 2016), San Francisco] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
AVEO Oncology announced that it has filed provisional patent applications with the United States Patent and Trademark Office covering composition of matter claims for AV-353, the company’s potent inhibitory antibody specific to Notch 3. [AVEO Pharmaceuticals, Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

Postdoctoral Fellow – Lung Disease (Oklahoma State University)

Senior Research Associate – Cell Biology (University College London)

Postdoctoral Fellow – Cell Biology (University of Chicago)

Postdoctoral Research Associate – Cancer Research (University of Leicester)

Faculty Positions – Basic or Translational Research (Cleveland Clinic)

Postdoctoral Research Fellow – Pancreatic and Lung Cancer (University of California – San Francisco)

Postdoctoral Fellows – Cancer Research (National University of Singapore)

Postdoctoral Fellowship – Genomics (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Positions – Tissue Repair/Inflammation (Institut Pasteur)

Postdoctoral Position or Research Scientist – Mucosal Immunology (Qu Biologics)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.